Abstract: Tobacco control policy seems to be based on a utilitarian principle that public health is best served by a range of measures that will provide overall population benefit. Aspirin may have a potential wider role since meta-analysis of randomized controlled trials shows it reduces the risk of a first vascular event and also cancer. Are smoking cessation and the public health potential of aspirin different? The benefit versus risk balance of aspirin, an inexpensive and easily available medicine, deserves serious consideration as a public health measure in middle age. Smoking cessation and wider aspirin use are not seen as either competing or duplicating policy areas, but complementary.
The World Health Organisation (WHO) recognizes the morbidity and mortality associated with smoking, including an increased risk of vascular events and cancer, as per the website link provided at the end of this commentary. Public health policy efforts to reduce smoking in the population are broad, intensive and sustained. One of the drivers for these efforts, which range from advertising bans to helping smokers quit, is to improve overall population health. The health risks of passive smoking are a further driver, with some countries now banning the use of tobacco products in public places. Whilst the public health view supported by WHO is that smoking is to discouraged, there are some points of controversy. For example, some smokers may feel disenfranchised, stigmatized and concerned that cessation policy compromises their freedom of choice. Furthermore, there may be some adverse health aspects of smoking cessation, such as weight gain [1] and the exacerbation of the gastrointestinal condition ulcerative colitis [2] .
Thus, the situation is not as clear cut as many public health professionals might believe and there are also complex vested interests, not least by the tobacco industry and also among companies with marketed smoking cessation products. A further consideration in this complex situation is that taxation from smoking can be a major contributor to gross domestic product whilst some pressure groups campaign for the freedom to enjoy their consumption of tobacco products. Hence policy is complex and needs to balance many competing views, of which health is only one.
Tobacco control policy seems to be based on a utilitarian principle that public health is best served by a range of measures that will provide overall population benefit. In achieving the benefits of reduced incidence of vascular events and cancer, some members within the target cohort will experience undesirable effects, namely inconvenience, psychological distress and exacerbation of a gastrointestinal condition. This utilitarian trade-off between benefits versus harms is also present in other public health situations, such as breast cancer screening [3] . How might the benefit versus harm trade-off inform the wider use of aspirin in the population?
To qualify this paper, smoking cessation and wider aspirin use are not seen as either competing or duplicating policy areas, but complementary. Their comparison has been purposefully selected because of common impacts, namely reduced vascular disease and cancer with increases in undesirable effects, notably gastrointestinal pathology. Part of the driver for this paper is to convey the message that public health policy has benefits and risks and the concept of a universally effective policy is unrealistic.
Aspirin use for the secondary prophylaxis of vascular events is a mainstream part of clinical practice. There are issues that remain to be addressed with aspirin and secondary prophylaxis, namely non-compliance. As a wider public health issue, aspirin may have a potential wider role since meta-analysis of randomized controlled trials shows it reduces the risk of a first vascular event [4] and also cancer [5] . The former benefit is small, perhaps 10% in a low risk population, while the latter benefit may take about 10 years to be observed. Of course aspirin also increases the risk of internal bleeding, usually in the gastrointestinal organs, although meta-analysis of randomized controlled trials suggest that this bleeding is usually minor, with no evidence of excess mortality [6] .
